POSEIDA THERAPEUTICS INC (PSTX) Stock Overview
USA - NASDAQ:PSTX - US73730P1084 - Common Stock
PSTX Key Statistics, Chart & Performance
The current stock price of PSTX is 9.5 USD. In the past month the price increased by 1.5%. In the past year, price increased by 211.48%.
PSTX Latest News, Press Relases and Analysis
PSTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.26 | 397.72B | ||
| AMGN | AMGEN INC | 13.38 | 157.08B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 89.25 | 50.61B | ||
| INSM | INSMED INC | N/A | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.58B | ||
| NTRA | NATERA INC | N/A | 26.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.24 | 21.68B |
Related stock screener links
About PSTX
Company Profile
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Company Info
POSEIDA THERAPEUTICS INC
9390 Towne Centre Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Eric Ostertag
Employees: 337
Phone: 18587793100
POSEIDA THERAPEUTICS INC / PSTX FAQ
Can you describe the business of POSEIDA THERAPEUTICS INC?
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
What is the stock price of POSEIDA THERAPEUTICS INC today?
The current stock price of PSTX is 9.5 USD. The price decreased by -0.63% in the last trading session.
Does POSEIDA THERAPEUTICS INC pay dividends?
PSTX does not pay a dividend.
What is the ChartMill rating of POSEIDA THERAPEUTICS INC stock?
PSTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for POSEIDA THERAPEUTICS INC?
POSEIDA THERAPEUTICS INC (PSTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for POSEIDA THERAPEUTICS INC?
POSEIDA THERAPEUTICS INC (PSTX) has a market capitalization of 925.97M USD. This makes PSTX a Small Cap stock.
PSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PSTX. When comparing the yearly performance of all stocks, PSTX is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
PSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTX. Both the profitability and financial health of PSTX have multiple concerns.
PSTX Financial Highlights
Over the last trailing twelve months PSTX reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 58.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| Debt/Equity | 0.68 |
PSTX Forecast & Estimates
10 analysts have analysed PSTX and the average price target is 9.18 USD. This implies a price decrease of -3.37% is expected in the next year compared to the current price of 9.5.
For the next year, analysts expect an EPS growth of 30.29% and a revenue growth 217.39% for PSTX